Meeting
2020 ASCO Virtual Scientific Program
Statistical modeling of a novel clinical trial design using neoadjuvant therapy (NAT) to personalize therapy in patients (pts) with triple-negative breast cancer (TNBC).
Authors
Stacy L. Moulder
The University of Texas MD Anderson Cancer Center, Houston, TX
Stacy L. Moulder , Roland L. Bassett Jr., Jason B White , Lei Huo , Senthil Damodaran , Bora Lim , Naoto T. Ueno , Rashmi Krishna Murthy , Banu Arun , Vicente Valero , Debu Tripathy , Gabriel N. Hortobagyi , Jennifer Keating Litton , Alastair Mark Thompson , Elizabeth A. Mittendorf , Elizabeth Ravenberg , Lumarie Santiago , Beatriz E Adrada , Rosalind P Candelaria , Gaiane M Rauch
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—Local/Regional/Adjuvant
Track
Breast Cancer
Sub Track
Neoadjuvant Therapy
Clinical Trial Registration Number
NCT02276443
Citation
J Clin Oncol 38: 2020 (suppl; abstr 595)
DOI
10.1200/JCO.2020.38.15_suppl.595
Abstract #
595
Poster Bd #
87
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
The impact of gut microbial composition on response to neoadjuvant chemotherapy (NACT) in early-stage triple negative breast cancer (TNBC).
First Author: Nour Abuhadra
Poster
2021 ASCO Annual Meeting
Neoadjuvant atezolizumab (atezo) and nab-paclitaxel (nab-p) in patients (pts) with triple-negative breast cancer (TNBC) with suboptimal clinical response to doxorubicin and cyclophosphamide (AC).
First Author: Clinton Yam
Poster
2020 ASCO Virtual Scientific Program
Prognostic impact of high stromal tumor-infiltrating lymphocytes (sTIL) in the absence of pathologic complete response (pCR) to neoadjuvant therapy (NAT) in early stage triple negative breast cancer (TNBC).
First Author: Nour Abuhadra
Poster
2020 ASCO Virtual Scientific Program
Comprehensive profiling of androgen receptor-positive (AR+) triple-negative breast cancer (TNBC) patients (pts) treated with standard neoadjuvant therapy (NAT) +/- enzalutamide.
First Author: Bora Lim